Finance

Lists
ORKA:NASDAQ
Oruka Therapeutics Inc
105,35 USD
+0,34%
(+0,36) 1D
13-ноя., 16:00:00 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ORKA...
Open
104,28 USD
High
106,87 USD
Low
101,56 USD
Mkt. cap
7,15 млд
Avg. vol.
973,48 миң
Volume
679,68 миң
52-wk high
115,52 USD
52-wk low
25,23 USD
EPS
-2,47 USD
Beta
-0,38
Shares outstanding
67,82 млн
No. of employees
68
Open
104,28 USD
High
106,87 USD
Low
101,56 USD
Mkt. cap
7,15 млд
Avg. vol.
973,48 миң
Volume
679,68 миң
52-wk high
115,52 USD
52-wk low
25,23 USD
EPS
-2,47 USD
Beta
-0,38
Shares outstanding
67,82 млн
No. of employees
68
News stories
From web sources and news partners
About Oruka Therapeutics Inc
CEO-
Employees68
Founded2024
HeadquartersВестминстер, Колорадо, Америка Кошмо Штаттары
SectorHealth Care
Industry-
Websiteorukatx.com
Analyst ratings
Based on 12 analysts giving stock ratings to ORKA in the past 3 months
Strong buy
Buy
12
Hold
0
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for ORKA in the last 3 months.
Highest
Current 105,35 USD
200,00 USD (+89,84%)
Average
153,60 USD (+45,80%)
Lowest
105,00 USD (-0,33%)
Analyst
Recommendation
Action
Price target
Projected
Date
Michael Yee
UBS
Buy
Maintained
130,00 USD
+23,4%
11/10/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
180,00 USD
+70,9%
11/10/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
200,00 USD
+89,8%
11/09/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Reiterated
150,00 USD
+42,4%
11/10/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
120,00 USD
+13,9%
11/10/2026
Julian Harrison
BTIG
Buy
Reiterated
151,00 USD
+43,3%
11/09/2026
Etzer Darout
Barclays
Buy
Maintained
160,00 USD
+51,9%
11/10/2026
David Risinger
Leerink Partners
Buy
Reiterated
-
-
10/27/2026
Martin Fan
Wedbush
Buy
Reiterated
165,00 USD
+56,6%
10/27/2026
Unknown Analyst
Wedbush
Buy
Reiterated
165,00 USD
+56,6%
10/27/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
105,00 USD
-0,3%
10/26/2026
David Nierengarten
Wedbush
Buy
Maintained
165,00 USD
+56,6%
09/24/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
175,00 USD
+66,1%
09/23/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
08/26/2026
Roger Song
Jefferies
Buy
Maintained
133,00 USD
+26,2%
08/11/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
200,00 USD
+89,8%
08/10/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
27,64 млн
29,14 млн
43,26 млн
53,70 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6,79 млн
7,29 млн
6,85 млн
8,44 млн
Operating expense
34,43 млн
36,43 млн
50,11 млн
62,14 млн
Total operating expenses
34,43 млн
36,43 млн
50,11 млн
62,14 млн
Operating income
-34,43 млн
-36,43 млн
-50,11 млн
-62,14 млн
Other non operating income
-1,00 миң
8,00 миң
4,00 миң
5,00 миң
EBT including unusual items
-29,58 млн
-31,82 млн
-41,21 млн
-49,96 млн
EBT excluding unusual items
-29,58 млн
-31,82 млн
-41,21 млн
-49,96 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-29,58 млн
-31,82 млн
-41,21 млн
-49,96 млн
Net profit margin
-
-
-
-
Earnings per share
-0,45
-0,48
-0,55
-0,63
Interest and investment income
4,85 млн
4,61 млн
8,90 млн
12,17 млн
Interest expense
-
-
-
-
Net interest expenses
4,85 млн
4,61 млн
8,90 млн
12,17 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-34,40 млн
-36,39 млн
-50,06 млн
-62,09 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору